rs80359455
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000059.4(BRCA2):c.4478_4481del(p.Glu1493ValfsTer10) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000472 in 1,461,498 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. L1491L?) has been classified as Pathogenic. Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.000047 ( 0 hom. )
Consequence
BRCA2
NM_000059.4 frameshift
NM_000059.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.45
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 13-32338827-TGAAA-T is Pathogenic according to our data. Variant chr13-32338827-TGAAA-T is described in ClinVar as [Pathogenic]. Clinvar id is 51653.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr13-32338827-TGAAA-T is described in Lovd as [Pathogenic]. Variant chr13-32338827-TGAAA-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BRCA2 | NM_000059.4 | c.4478_4481del | p.Glu1493ValfsTer10 | frameshift_variant | 11/27 | ENST00000380152.8 | NP_000050.3 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BRCA2 | ENST00000380152.8 | c.4478_4481del | p.Glu1493ValfsTer10 | frameshift_variant | 11/27 | 5 | NM_000059.4 | ENSP00000369497 | A2 |
Frequencies
GnomAD3 genomes
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250362Hom.: 0 AF XY: 0.00000738 AC XY: 1AN XY: 135544
GnomAD3 exomes
AF:
AC:
4
AN:
250362
Hom.:
AF XY:
AC XY:
1
AN XY:
135544
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000472 AC: 69AN: 1461498Hom.: 0 AF XY: 0.0000440 AC XY: 32AN XY: 727050
GnomAD4 exome
AF:
AC:
69
AN:
1461498
Hom.:
AF XY:
AC XY:
32
AN XY:
727050
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:28
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:8
| Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Apr 22, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
| Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Feb 20, 2013 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Molecular Endocrinology Laboratory, Christian Medical College | - | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | May 29, 2002 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 13, 2023 | This variant deletes 4 nucleotides in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in over 10 individuals affected with ovarian cancer (PMID: 11972384, 20406929, 21324516, 22711857, 23165508, 23791828, 23884708, 24728189), and individuals affected with breast cancer (PMID: 20950396, 22798144, 33758026, 33471991; Leiden Open Variation Database DB-ID BRCA2_001792, Color internal data). This variant has been identified in 4/250362 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
| Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Sep 04, 2014 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Mar 02, 2020 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
not provided Pathogenic:7
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 07, 2023 | The BRCA2 c.4478_4481del; p.Glu1493ValfsTer10 variant (rs80359454), also known as 4706del for legacy nomenclature, is reported in multiple individuals and families with hereditary breast and ovarian cancer syndrome (Dudley 2018, Kote-Jarai 2011, Le 2022, Tavtigian 1996, Zhang 2011). This variant is also classified as pathogenic by an expert review panel in the ClinVar Database (Variation ID: 51653). It is observed on four alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This variant causes a frameshift by deleting four nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Dudley B et al. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Cancer. 2018 Apr 15;124(8):1691-1700. PMID: 29360161. Kote-Jarai Z et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011 Oct 11;105(8):1230-4. PMID: 21952622. Le TN et al. BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome. Genes (Basel). 2022 Jan 29;13(2):268. PMID: 35205313. Tavtigian SV et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996 Mar;12(3):333-7. PMID: 8589730. Zhang S et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011 May 1;121(2):353-7. PMID: 21324516. - |
| Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2023 | BRCA2: PVS1, PM2 - |
| Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 20, 2021 | This variant alters the translational reading frame of the BRCA2 mRNA and causes the premature termination of BRCA2 protein synthesis. This variant has been reported in individuals and families affected with breast or ovarian cancer in the published literature (PMID: 27153395 (2016), 23884708 (2014), 22798144 (2012), 21952622 (2011), 21324516 (2011)). Based on the available information, this variant is classified as pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 28, 2021 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Observed in individuals with hereditary breast and ovarian cancer (Tavtigian 1996, Meindl 2002, Zhang 2011, Kim 2012, Dudley 2018); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at a significant frequency in large population cohorts (Lek 2016); This variant is associated with the following publications: (PMID: 27488020, 27836010, 26681312, 29360161, 30720243, 28176296, 8589730, 11802209, 21324516, 22798144, 21952622, 26187060, 23569316, 10359546, 17148771, 9667259, 20927582, 16162645, 27225637, 29371908, 29478780, 29915322, 27153395, 11179017, 15131399, 30702160, 30322717, 32885271, 32338768) - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 02, 2022 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:5
| Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 14, 2019 | The p.Glu1493ValfsX10 variant in BRCA2 has been reported in >20 individuals with BRCA2-related cancers and segregated with disease in 12 individuals from one family (Tavtigian 1996, Kote-Jarai 2011, Zhang 2011, Maxwell 2016, Susswein 2016, Shi 2017, AlDubayan 2018, Dudley 2018, Mijuskovic 2018, BIC database). It has also been identified in 0.0035% (4/112994) European chromosomes by gnomAD (http://gnomad.broadinstitute.org); however, this frequency is low enough to be consistent with the frequency of hereditary breast and ovarian cancer (HBOC) in the general population. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1493 and leads to a premature termination codon 10 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the BRCA2 gene is an established disease mechanism in autosomal dominant HBOC. Additionally, this variant was classified as Pathogenic on Apr 22 2016 by the ClinGen-approved ENIGMA expert panel (Variation ID: 51653). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PVS1, PS4, PP1_Strong, PM2. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change creates a premature translational stop signal (p.Glu1493Valfs*10) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs776022857, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with female breast and ovarian cancer, male breast cancer, and prostate cancer (PMID: 8589730, 11179017, 15131399, 20927582, 21324516, 21952622, 22798144). This variant is also known as 4706del4. ClinVar contains an entry for this variant (Variation ID: 51653). For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 04, 2016 | Variant summary: The BRCA2 variant, c.4478_4481delAAAG (p.Glu1493Valfs), causes a frameshift resulting in a premature stop codon, a known mechanism for disease, as these types of variants are predicted to cause transcript degradation through nonsense mediated decay or produce a truncated protein. The variant of interest was not observed in controls (ExAC, 1000 Gs, or ESP) and has been reported in multiple affected individuals via publications. In addition, multiple reputable clinical laboratories/databases cite the variant with a classification of "pathogenic." Therefore, the variant of interest is classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Department of Pathology and Molecular Medicine, Queen's University | Apr 20, 2017 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:2
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 06, 2021 | The c.4478_4481delAAAG pathogenic mutation, located in coding exon 10 of the BRCA2 gene, results from a deletion of 4 nucleotides at nucleotide positions 4478 to 4481, causing a translational frameshift with a predicted alternate stop codon (p.E1493Vfs*10). This pathogenic mutation has been reported in multiple families affected with breast, ovarian and/or prostate cancer (Tavtigian SV et al. Nat. Genet., 1996 Mar;12:333-7; Frank TS et al. J Clin Oncol, 1998 Jul;16:2417-25; Risch HA et al. Am J Hum Genet, 2001 Mar;68:700-10; Lubinski J et al. Fam Cancer, 2004;3:1-10; Ding YC et al. Breast Cancer Res Treat, 2011 Apr;126:771-8; Zhang S et al. Gynecol Oncol, 2011 May;121:353-7; Kote-Jarai Z et al. Br J Cancer, 2011 Oct;105:1230-4; Kim H et al. Breast Cancer Res Treat, 2012 Aug;134:1315-26; McVeigh TP et al. Ir J Med Sci, 2014 Jun;183:199-206; Maxwell KN et al. Am J Hum Genet, 2016 May;98:801-817; Shi T et al. Int J Cancer, 2017 05;140:2051-2059; Dudley B et al. Cancer, 2018 04;124:1691-1700; Mijuskovic M et al. Br J Cancer, 2018 07;119:96-104; Carter NJ et al. Gynecol Oncol, 2018 12;151:481-488; Bhaskaran SP et al. Int J Cancer, 2019 08;145:962-973; Nguyen-Dumont T et al. Int J Cancer, 2020 10;147:2142-2149; Lattimore V et al. Breast Cancer Res Treat, 2021 Feb;185:583-590; Dorling et al. N Engl J Med. 2021 02;384:428-439). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 11, 2023 | This variant deletes 4 nucleotides in exon 11 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in over 10 individuals affected with ovarian cancer (PMID: 11972384, 20406929, 21324516, 22711857, 23165508, 23791828, 23884708, 24728189), and individuals affected with breast cancer (PMID: 20950396, 22798144, 33758026, 33471991; Leiden Open Variation Database DB-ID BRCA2_001792, Color internal data). This variant has been identified in 4/250362 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jul 31, 2024 | Criteria applied: PVS1,PM5_STR,PM2_SUP - |
Breast and/or ovarian cancer Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jun 01, 2023 | - - |
Gastric cancer Pathogenic:1
| Pathogenic, no assertion criteria provided | research | Laboratory for Genotyping Development, RIKEN | Jul 01, 2021 | - - |
Malignant tumor of breast Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRCA2 p.Glu1493Valfs*10 variant was identified in 12 of 17460 proband chromosomes (frequency: 0.0007) from individuals or families with prostate, breast or ovarian cancer (Beetstra 2006, Ding 2011, Fong 2010, Kim 2012, Kote-Jarai 2011, Lubinski 2004, Peto 1999, Risch 2001, Zhang 2011). The variant was also identified in dbSNP (ID: rs80359454) as "With Pathogenic allele", ClinVar (classified as pathogenic by Invitae, Ambry Genetics, GeneDx and twelve other submitters), LOVD 3.0 (19x as pathogenic ), and UMD-LSDB (1x as causal). The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The variant was shown to have a partial response to platinum-based therapy according to the Response Evaluation Criteria in Solid Tumors and Gynecologic Cancer Intergroup Response criteria (Fong 2010). The c.4478_4481del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 1493 and leads to a premature stop codon at position 1502. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer (HBOC) and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic. - |
Familial cancer of breast Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 13, 2021 | - - |
Diffuse intrinsic pontine glioma Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Jun 09, 2017 | This is a frameshift alteration in which four nucleotides are deleted (coding nucleotides 4478 through 4481) and is predicted to change a Glutamic Acid to a Valine at amino acid codon 1493, shift the reading frame and result in a premature stop codon 10 amino acids downstream. Classification criteria: PVS1, PM2, PP1. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at